AQUA Therapeutics Overview
- Year Founded
-
2012
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Out of Business
AQUA Therapeutics General Information
Description
Provider of medical research and consulting services intended to treat fibrotic diseases. The company's services produce drugs through conventional drug discovery technology, low molecule, and antibody drugs, enabling the healthcare industry to develop innovative therapeutic drugs using nucleic acid drugs in order to bring about a major change in the treatment of all fibrotic diseases.
Contact Information
Website
www.aqua-therapeutics.comCorporate Office
- Sannomiya Denden Building 3F
- 64 Naniwamachi,Chuo-ku
- Kobe
- Japan
Corporate Office
- Sannomiya Denden Building 3F
- 64 Naniwamachi,Chuo-ku
- Kobe
- Japan
AQUA Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Out of Business | 15-Oct-2021 | Completed | Out of Business | |||
| 3. Secondary Transaction - Private | 01-Aug-2021 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 11-Sep-2015 | $4.09M | $9.1M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 01-Aug-2013 | $5.02M | $5.02M | Completed | Generating Revenue |
AQUA Therapeutics Patents
AQUA Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2018030451-A1 | Therapeutic agent for adhesion, method for treating adhesion, postoperative adhesion marker, and method for examining susceptibility to postoperative adhesion | Inactive | 09-Aug-2016 | ||
| WO-2017026496-A1 | Periostin gene expression-suppressing nucleic acid molecule, method for suppressing expression of periostin gene, and application therefor | Inactive | 10-Aug-2015 | ||
| EP-3047852-A1 | Drug for disease caused by expression of periostin except eye disease, and use thereof | Inactive | 27-Sep-2013 | ||
| US-20160304866-A1 | Drug for disease caused by expression of periostin except eye disease, and use thereof | Inactive | 27-Sep-2013 | ||
| WO-2015046451-A1 | Drug for disease caused by expression of periostin except eye disease, and use thereof | Inactive | 27-Sep-2013 | C12N15/113 |
AQUA Therapeutics Signals
AQUA Therapeutics FAQs
-
When was AQUA Therapeutics founded?
AQUA Therapeutics was founded in 2012.
-
Where is AQUA Therapeutics headquartered?
AQUA Therapeutics is headquartered in Kobe, Japan.
-
What is the size of AQUA Therapeutics?
AQUA Therapeutics has 2 total employees.
-
What industry is AQUA Therapeutics in?
AQUA Therapeutics’s primary industry is Drug Discovery.
-
Is AQUA Therapeutics a private or public company?
AQUA Therapeutics is a Private company.
-
What is AQUA Therapeutics’s current revenue?
The current revenue for AQUA Therapeutics is .
-
How much funding has AQUA Therapeutics raised over time?
AQUA Therapeutics has raised $9.1M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process